The Latest Breaking News from Seagen

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 5.77% on an annualized basis producing an average annual return of 17.01%. Currently, Seagen has a market capitalization of $26.17 billion.

Seagen Inc (NASDAQ:SGEN) announced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients.  Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG (OTC:RHHBY). Data from this trial will form the basis of a planned supplemental…

Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.

Seagen (NASDAQ:SGEN) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seagen beat estimated earnings by 26.0%, reporting an EPS of $-0.74 versus an estimate of $-1.0.

Sanofi SA (NASDAQ:SNY) and Seagen Inc (NASDAQ:SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets.  The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology.  ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing…

Here's a roundup of top developments in the biotech space over the last 24 hours.

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) 

Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the last quarter:

Seagen offered a disappointing outlook for 2022 as AstraZeneca pressures its new breast cancer drug, leading SGEN stock to dive on Thursday.